Celcuity Inc. CELC · Stock Open Celcuity Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Celcuity Inc. Analysis (CELC)
Is Celcuity Inc. a good investment? Celcuity Inc. (CELC) is currently trading at 69.24 USD. Market analysts have a consensus price target of 154.72 USD. This suggests a potential upside from current levels.
Earnings Schedule: Celcuity Inc. is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -0.08.
Investor FAQ
Does Celcuity Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Celcuity Inc.?
Celcuity Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of -4.31.
Company Profile
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
Community Discussion